JP2013542994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542994A5 JP2013542994A5 JP2013539949A JP2013539949A JP2013542994A5 JP 2013542994 A5 JP2013542994 A5 JP 2013542994A5 JP 2013539949 A JP2013539949 A JP 2013539949A JP 2013539949 A JP2013539949 A JP 2013539949A JP 2013542994 A5 JP2013542994 A5 JP 2013542994A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- pharmaceutically acceptable
- heteroaryl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims 19
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- -1 salts compound Chemical class 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical group C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical group N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000008640 Pulmonary Atresia Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41415810P | 2010-11-16 | 2010-11-16 | |
| US61/414,158 | 2010-11-16 | ||
| US201161503286P | 2011-06-30 | 2011-06-30 | |
| US61/503,286 | 2011-06-30 | ||
| PCT/US2011/060791 WO2012068109A2 (en) | 2010-11-16 | 2011-11-15 | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016157532A Division JP2017019820A (ja) | 2010-11-16 | 2016-08-10 | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542994A JP2013542994A (ja) | 2013-11-28 |
| JP2013542994A5 true JP2013542994A5 (OSRAM) | 2015-01-08 |
| JP6041808B2 JP6041808B2 (ja) | 2016-12-14 |
Family
ID=46047943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539949A Active JP6041808B2 (ja) | 2010-11-16 | 2011-11-15 | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
| JP2016157532A Pending JP2017019820A (ja) | 2010-11-16 | 2016-08-10 | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016157532A Pending JP2017019820A (ja) | 2010-11-16 | 2016-08-10 | 蛋白質脱アセチル化酵素抑制剤としてのピリミジン水酸基アミド化合物およびその利用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8614223B2 (OSRAM) |
| EP (2) | EP3067346A1 (OSRAM) |
| JP (2) | JP6041808B2 (OSRAM) |
| KR (1) | KR20130115300A (OSRAM) |
| CN (2) | CN107011270A (OSRAM) |
| AU (2) | AU2011329028B2 (OSRAM) |
| BR (1) | BR112013011868A2 (OSRAM) |
| CA (1) | CA2818125A1 (OSRAM) |
| CL (1) | CL2013001381A1 (OSRAM) |
| EA (2) | EA201691121A1 (OSRAM) |
| ES (1) | ES2568260T3 (OSRAM) |
| IL (2) | IL226326A0 (OSRAM) |
| MX (1) | MX2013005392A (OSRAM) |
| NZ (2) | NZ710405A (OSRAM) |
| PH (2) | PH12013500964A1 (OSRAM) |
| PL (1) | PL2640709T3 (OSRAM) |
| PT (1) | PT2640709T (OSRAM) |
| SG (2) | SG190211A1 (OSRAM) |
| WO (1) | WO2012068109A2 (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3091004B1 (en) | 2010-01-22 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP3067346A1 (en) | 2010-11-16 | 2016-09-14 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| JP2015515279A (ja) | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
| EP2906211A4 (en) * | 2012-10-12 | 2016-04-20 | Univ Pennsylvania | PYRIMIDINHYDROXY AMID COMPOUNDS AS A PROTEIN DEACETYLASE INHIBITOR AND METHOD OF USE THEREOF |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| EP2968207A4 (en) * | 2013-03-14 | 2016-09-28 | Chdi Foundation Inc | HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS |
| WO2014159224A1 (en) | 2013-03-14 | 2014-10-02 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2015042418A1 (en) * | 2013-09-20 | 2015-03-26 | Acetylon Pharmaceuticals, Inc. | Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor |
| JP6626437B2 (ja) * | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ |
| US20150105383A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| WO2015054474A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| US20150105409A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma |
| PE20161342A1 (es) * | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
| JP2016534069A (ja) * | 2013-10-24 | 2016-11-04 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療 |
| CN105939716A (zh) * | 2013-12-03 | 2016-09-14 | 埃斯泰隆制药公司 | 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合 |
| JP7017309B2 (ja) | 2013-12-20 | 2022-02-08 | アセチロン ファーマシューティカルズ インコーポレイテッド | 多発性骨髄腫におけるヒストン脱アセチル化酵素６（ｈｄａｃ６）バイオマーカー |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| CN104974108B (zh) * | 2014-04-04 | 2017-11-17 | 中国科学院上海药物研究所 | 一类2,2’‑串联双噻唑类化合物及其制备方法和用途 |
| CA2951026A1 (en) | 2014-06-02 | 2015-12-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| JP6952602B2 (ja) * | 2014-07-07 | 2021-10-20 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤による白血病の治療 |
| WO2016090230A1 (en) * | 2014-12-05 | 2016-06-09 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds for treating peripheral neuropathy |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| HK1251566A1 (zh) | 2014-12-12 | 2019-02-01 | Regenacy Pharmaceuticals, Llc | 作为hdac1/2抑制剂的呱啶衍生物 |
| CN104503831B (zh) * | 2014-12-22 | 2017-10-13 | 北京奇虎科技有限公司 | 设备优化方法及装置 |
| SG10202100916PA (en) | 2015-02-02 | 2021-02-25 | Valo Early Discovery Inc | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| KR102015826B1 (ko) * | 2015-04-21 | 2019-08-29 | 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 | 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도 |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| WO2016200930A1 (en) | 2015-06-08 | 2016-12-15 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
| JP6816036B2 (ja) | 2015-06-08 | 2021-01-20 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストン脱アセチル化阻害剤の結晶形態 |
| US10040769B2 (en) | 2015-10-27 | 2018-08-07 | Regenacy Pharmaceuticals, Llc | HDAC inhibitors for the treatment of diabetic peripheral neuropathy |
| JP2019515909A (ja) | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物 |
| US10206925B2 (en) * | 2016-06-07 | 2019-02-19 | Eisai R&D Management Co, Ltd. | Topical formulations of PDE-4 inhibitors and their methods of use |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
| JP7068297B2 (ja) | 2016-11-10 | 2022-05-16 | アセチロン ファーマシューティカルズ インコーポレイテッド | フェニル及びピリジニルヒドロキサム酸 |
| JP7090611B2 (ja) | 2016-11-23 | 2022-06-24 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法 |
| CA3049834A1 (en) * | 2017-01-10 | 2018-07-19 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Hdac6 selective inhibitors, preparation method therefor, and application thereof |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| EP3609864B1 (en) * | 2017-04-11 | 2024-03-13 | The General Hospital Corporation | Hdac6 inhibitors and imaging agents |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| KR102236356B1 (ko) * | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
| CN108299313B (zh) * | 2018-01-16 | 2020-10-02 | 长沙霍滋生物科技有限公司 | 一种化合物及其在药学上的应用 |
| CN108129367B (zh) * | 2018-02-05 | 2020-10-02 | 南开大学 | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 |
| KR20190099952A (ko) * | 2018-02-20 | 2019-08-28 | 주식회사 종근당 | 포도막염의 예방 또는 치료를 위한 조성물 |
| JP7348214B2 (ja) * | 2018-07-04 | 2023-09-20 | シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッド | Ｈｄａｃ６選択的阻害剤の結晶形及びその使用 |
| US20220296599A1 (en) * | 2018-10-12 | 2022-09-22 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate |
| CN111848454B (zh) * | 2019-04-28 | 2021-05-07 | 山东大学 | 一种组蛋白去乙酰化酶6抑制剂及其制备方法和应用 |
| WO2021110121A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Hdac6选择性抑制剂及其组合疗法 |
| CN114315736B (zh) * | 2020-03-30 | 2025-11-18 | 甫康（上海）健康科技有限责任公司 | 二氢化茚胺类衍生物、其制备方法和用途 |
| JP2023530788A (ja) * | 2020-06-08 | 2023-07-19 | アンジー ファーマシューティカル カンパニー リミテッド | 選択的ｈｄａｃ６阻害剤として有用なキナゾリン誘導体 |
| CN112029738B (zh) * | 2020-08-18 | 2022-04-29 | 浙江省人民医院 | 人parkin蛋白乙酰化及其在药物制备中的应用 |
| CN113024536B (zh) * | 2021-03-12 | 2022-05-27 | 湖南师范大学 | 含嘧啶-哌嗪环的5-氨基噻唑甲酰胺类化合物及其制备方法和用途 |
| WO2023150203A1 (en) * | 2022-02-03 | 2023-08-10 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3549633A (en) * | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
| US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
| US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
| US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
| US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| BR0213791A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Derivados de amida como inibidores de glicogênio sintase quinase 3-beta |
| US6517889B1 (en) | 2001-11-26 | 2003-02-11 | Swaminathan Jayaraman | Process for coating a surface of a stent |
| CN1305850C (zh) * | 2002-03-13 | 2007-03-21 | 詹森药业有限公司 | 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物 |
| OA12790A (en) * | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase. |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| MY141521A (en) * | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| HRP20070057T3 (hr) * | 2003-07-24 | 2007-07-31 | Basf Aktiengesellschaft | 2-supstituirani pirimidini |
| WO2005030705A1 (en) * | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JP4993374B2 (ja) | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| CA2601706C (en) | 2005-03-22 | 2016-09-20 | Dana-Farber Cancer Institute, Inc. | Treatment of protein degradation disorders |
| GB0510204D0 (en) * | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| KR20080052611A (ko) * | 2005-08-26 | 2008-06-11 | 메틸진 인크. | 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제 |
| ATE554084T1 (de) * | 2006-02-07 | 2012-05-15 | Astellas Pharma Inc | N-hydroxyacrylamidverbindungen |
| EP1991247B1 (en) | 2006-02-14 | 2015-10-14 | President and Fellows of Harvard College | Bifunctional histone deacetylase inhibitors |
| AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
| CA2667826C (en) * | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| RU2501787C2 (ru) * | 2007-11-02 | 2013-12-20 | Метилджен Инк. | Ингибиторы гистондеацетилазы |
| WO2009137462A2 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137503A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
| WO2010009155A2 (en) * | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitor compounds |
| EP2321264B1 (en) | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
| ME02230B (me) * | 2009-01-08 | 2016-02-20 | Curis Inc | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| EP2401123A4 (en) | 2009-02-26 | 2013-08-28 | Arkema Inc | ROTOMOULE ARTICLE FORMED FROM HIGH MOLECULAR WEIGHT POLYAMIDES |
| WO2011011186A2 (en) * | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
| US20130040998A1 (en) | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
| EP3091004B1 (en) | 2010-01-22 | 2017-12-13 | Acetylon Pharmaceuticals, Inc. | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2012018499A2 (en) * | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| EP3067346A1 (en) | 2010-11-16 | 2016-09-14 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2524918A1 (en) * | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| JP2015515279A (ja) | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| US9096549B2 (en) | 2013-02-01 | 2015-08-04 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| JP2016523236A (ja) | 2013-06-03 | 2016-08-08 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 多発性骨髄腫におけるヒストン脱アセチル化酵素（ｈｄａｃ）バイオマーカー |
| JP6626437B2 (ja) | 2013-10-08 | 2019-12-25 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| WO2015054474A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| US20150105409A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma |
| PE20161342A1 (es) | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
| CN105939716A (zh) | 2013-12-03 | 2016-09-14 | 埃斯泰隆制药公司 | 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合 |
-
2011
- 2011-11-15 EP EP16150961.7A patent/EP3067346A1/en not_active Withdrawn
- 2011-11-15 KR KR1020137015474A patent/KR20130115300A/ko not_active Ceased
- 2011-11-15 ES ES11840803.8T patent/ES2568260T3/es active Active
- 2011-11-15 NZ NZ710405A patent/NZ710405A/en not_active IP Right Cessation
- 2011-11-15 NZ NZ610225A patent/NZ610225A/en not_active IP Right Cessation
- 2011-11-15 SG SG2013035498A patent/SG190211A1/en unknown
- 2011-11-15 AU AU2011329028A patent/AU2011329028B2/en not_active Ceased
- 2011-11-15 BR BR112013011868A patent/BR112013011868A2/pt not_active IP Right Cessation
- 2011-11-15 CA CA2818125A patent/CA2818125A1/en not_active Abandoned
- 2011-11-15 US US13/296,748 patent/US8614223B2/en active Active
- 2011-11-15 MX MX2013005392A patent/MX2013005392A/es active IP Right Grant
- 2011-11-15 EA EA201691121A patent/EA201691121A1/ru unknown
- 2011-11-15 SG SG10201509324QA patent/SG10201509324QA/en unknown
- 2011-11-15 CN CN201610911460.9A patent/CN107011270A/zh active Pending
- 2011-11-15 CN CN201180055168.7A patent/CN103429574B/zh not_active Expired - Fee Related
- 2011-11-15 EP EP11840803.8A patent/EP2640709B1/en active Active
- 2011-11-15 PL PL11840803.8T patent/PL2640709T3/pl unknown
- 2011-11-15 EA EA201390711A patent/EA025345B1/ru not_active IP Right Cessation
- 2011-11-15 JP JP2013539949A patent/JP6041808B2/ja active Active
- 2011-11-15 PH PH1/2013/500964A patent/PH12013500964A1/en unknown
- 2011-11-15 WO PCT/US2011/060791 patent/WO2012068109A2/en not_active Ceased
- 2011-11-15 PT PT118408038T patent/PT2640709T/pt unknown
-
2013
- 2013-05-13 IL IL226326A patent/IL226326A0/en unknown
- 2013-05-15 CL CL2013001381A patent/CL2013001381A1/es unknown
- 2013-11-18 US US14/082,472 patent/US9409890B2/en active Active
-
2015
- 2015-04-16 PH PH12015500832A patent/PH12015500832A1/en unknown
-
2016
- 2016-07-06 US US15/203,023 patent/US20170096403A1/en not_active Abandoned
- 2016-08-10 JP JP2016157532A patent/JP2017019820A/ja active Pending
- 2016-12-02 AU AU2016266069A patent/AU2016266069A1/en not_active Abandoned
- 2016-12-15 IL IL249594A patent/IL249594A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542994A5 (OSRAM) | ||
| JP2013536235A5 (OSRAM) | ||
| JP2013545810A5 (OSRAM) | ||
| JP2011525192A5 (OSRAM) | ||
| ES2794779T3 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK | |
| CN104672225B (zh) | 二氢嘧啶衍生物的制备方法及其中间体 | |
| JP2008504301A5 (OSRAM) | ||
| KR100843848B1 (ko) | Ｈ3 리간드로서 유용한 3- 또는 4-단일치환된 페놀 및싸이오페놀 유도체 | |
| JP2018531982A5 (OSRAM) | ||
| AU2009274355B2 (en) | Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as FAAH enzyme inhibitors | |
| JP2013525433A5 (OSRAM) | ||
| HRP20161367T1 (hr) | Spojevi reverznog amida kao inhibitori protein deacetilaze i postupci za njihovu uporabu | |
| JP2016513660A5 (OSRAM) | ||
| JP2012529535A5 (OSRAM) | ||
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| JP2015502387A5 (OSRAM) | ||
| JP2017511357A5 (OSRAM) | ||
| JP2009510097A5 (OSRAM) | ||
| KR20150047136A (ko) | 융합 바이사이클릭 설파모일 유도체 및 b형 간염 치료제로서의 그 용도 | |
| JP2009263394A5 (OSRAM) | ||
| JP2010540504A (ja) | ニコチンアミド誘導体、これらの調製およびこれらの治療目的使用 | |
| JP2009539848A5 (OSRAM) | ||
| CA2595574A1 (en) | Chemical compounds | |
| KR20110133049A (ko) | 항암 약물로서의 니코틴아미드 유도체, 그의 제조법 및 그의 치료 용도 | |
| JP2015516968A5 (OSRAM) |